Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10380 in Acute Schizophrenia
NCT07911787Phase 3Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 3 trial of obuprazine in schizophrenia, sponsored by Hansoh Pharmaceutical Group. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
obuprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07911787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07911787.